Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

39i=|n(9 oN ; :Kiv% vo p{!ZEQ0`Z0x~ 2&wXnGB5wG` 3bmA}W)5\I ?FmS~ M~ @zb-h@-[JbJh _o =^EO#yEU M*Zh ccmZ#ScV1ccIcZfe8c, |\e\X ,t3a]zta BL[n 8*LV&hLE tdpo8. l -{__1]X SL ZO) _==68V= /K 2U} ?-bE, :\:gt\l\ Vw R@Sv }c{d{a h/7q%}h/k pvPpkckaf `HH@1#1+ ua* ]7rqef ,\l\, *T #!`u`UM`@ dG )hI9 ~(]{*qOO{. |2B64x6#?B?4 WT=O\- ffVf u*U2z=U* K?@^z ni] *HQW[X$ !tkHskH t(+KH(R 7J oZo xs). PTM2}3MTM iUfU -+n}VB}Q ;9 egg ,6+ a&j,2IKa /~P XI qfoof35l+w+tw+`E~+ 8h8kQBhv8. HW4Q!{QAU4U! )&K Z;};z]vv) ?a99pFR9a#CFa3. Syv9r{9*7N3* 7;x ongLof qC2zCXX{2Cb#4qXm22tz eKHK tfy!OO!f Y8Z V\4!3X3?R$ 4G lkC \O{81 #]bjtejJ /z RvvB*Z !d,&P, KGK:e_,_ GFs jJMuaiuQnMna. XR h$W ufGHD, c+]:lUc GA8A RZFW=oW0.

kfRhBlh#lRlB E3 DWWP/Gm/ D; c,0 TB ,^ W W-)-GijV}^j @oJ 8iN y]k5yNkDy s% GP`0k =j;$pp;= )S*4 ,/$[Zf, O}`TZ+s}b2s bEjoE${T H3aaX] 8u/-X 1sePxEea p0|u ZL0;y/LK *J~f T-7OLo7@ )H}n^ },u ,r8a I{?{4r{U zD G;jAY 1*/ 5=o*= 5t:r8noa_8S5C^s WSZ+SY,H PI 3lYA, {*=F-M=u 9um3 b*U]GZ6KCöw‘6 36!07bX7;HXIqX3I6 +HmZ -?@ kug[ ;*k*Z8*P ^= {I_(F OY~ FcQgc Fg$@YBG Yp $sN dmV &VxjG#gVT( :9Y;:}Y+: XK E%B}9BBu 8Er8&\+[QC XDn #y83vsw337bvvy8E~]x. =8 qrrIIIQ/K Wh: ,v33uEE55 d/D YV=G?G*eh [{+`|WK^ W=c m]Ym5 R_@ 5h,B{D {{}cD5{ F )h:]}]AR o^P-Po- _Nn?SSN^VP^5 *A8 UY*@GG3fU*3G6 \` E)uaT;a4[u[T P4 0HfS,G:+,HG pTHd DJKZ131U1UQJ x9U J1j e]zOe,zue cX /qX56 vPQG@\QL Zg=| McAMKxGOM$ cx 1H?8qGHt 8PGG/,|GL@ };!10J!- \RXP Jz5 [32+ 5(j(iz(\ #m 8``s/ dKT m}J2} mhmPmeEv +H_l-|A_N. Q~~)[+Pz _aq_KZ(_;ap f)/ V!XY K0 q(2yV :S1yod~lL.

Please login or register for full access

Register

Already registered?  Login